ClinicalTrials.gg
Not yet recruitingNCT07941570TM2SUpdated Nov 17, 2026

The Impact of Using a Non-motorised Physical Assistance Device on the Prevention of Musculoskeletal Disorders Amongst Care-givers

An interventional study of Non-motorized DAP in Musculoskeletal Disorders, sponsored by Pôle Saint Hélier. Not yet recruiting at 3 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Pôle Saint Hélier · Not applicable, Interventional, and Prevention

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This experimental study uses a Single-Case Experimental Design (SCED) with multiple baselines across participants to evaluate the impact of a non motorized assistive device (DAP) on muscle effort in care givers during their professional activities. Each participant completes a 12-day protocol consisting of three phases (A1 - B - A2), with the initial baseline (A1, no device) randomized between 2 and 6 days, followed by a 6-day intervention phase (B, wearing the non-motorized DAP), and a final withdrawal phase (A2, no device) adjusted to complete the 12-day period. Muscle effort is continuously quantified as a percentage of maximum voluntary contraction using mechanomyographic sensors (MOTEN Technologies) placed on the lumbar and biceps muscles, as well as the quadriceps at the Fondation Saint-Hélier site.

02

Conditions studied

  • Musculoskeletal Disorders
03

In context

Musculoskeletal Diseases

753 studies on the registry are indexed under Musculoskeletal Diseases; 164 are open to participants now.

This study's planned enrollment of 9 is below the median of 76 across 519 interventional studies indexed under Musculoskeletal Diseases.

Browse Musculoskeletal Diseases studies →

Lead sponsor

Pôle Saint Hélier is the lead sponsor of 23 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years and older.
  • Height between 160 cm and 200 cm.
  • Professional care-giver working in SMR (Medical and Rehabilitation Care) or medico-social departments of partner healthcare facilities.
  • Willing to wear the non-motorized DAP under the conditions defined by the protocol.
  • Affiliated with or beneficiary of a national social security scheme.
  • Having provided free and informed written consent.

Exclusion criteria

Exclusion Criteria:

  • Self-reported back, leg, or knee pathology that raises doubts regarding the safe use of the non-motorized DAP without prior medical clearance.
  • Pregnant, parturient, or breastfeeding women.
  • Persons deprived of liberty by a judicial or administrative decision (including legal guardianship, trusteeship, or court protection).
  • Persons receiving psychiatric care or admitted to a healthcare or social establishment for reasons other than research.
  • Persons in emergency situations unable to express prior .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Non-motorized DAP Intervention

    Single group following a 12-day A1-B-A2 SCED protocol. Participants undergo a randomized baseline of 2-6 days without the device (A1), a 6-day intervention phase wearing the non-motorized DAP during work activities (B), and an adjusted withdrawal phase without the device (A2).

    Device: Non-motorized DAP

Interventions

  • DeviceNon-motorized DAP

    Participants wear a non-motorized device for posture assistance (DAP) during their regular professional activities as nurse's aides for 6 consecutive days (Phase B of the 12-day A1-B-A2 SCED protocol). Muscle effort is continuously monitored using mechanomyographic sensors (MOTEN Technologies).

    Also known as: Non-motorized posture-assistive device, Physical assistance device

06

What researchers measure

Primary outcomes

  1. Percentage of Maximum Voluntary Contraction (% MVC) of target muscle groups

    Muscle effort is continuously quantified via mechanomyography (MMG) using MOTEN Technologies sensors. The primary outcome is the muscle effort level expressed as a percentage of the individual's maximum voluntary contraction (% MVC) for each monitored muscle group (lumbar and biceps muscles across all sites; quadriceps muscles at the Fondation Saint-Hélier site). Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases.

    Time frame: Daily during work hours over the 12-day study protocol

Secondary outcomes

  1. Change in postural strain measured by mechanomyography (MMG)

    Postural strain during daily professional activities is evaluated using mechanomyographic (MMG) sensors (MOTEN Technologies) placed on target muscle groups. Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases.

    Time frame: Daily during work hours over the 12-day study protocol

  2. Change in perceived effort score using a Numerical Rating Scale (NRS)

    Perceived exertion during work tasks is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low effort and 10 represents very high effort.

    Time frame: Twice daily (after each half-day work shift) over the 12-day study protocol

  3. Change in perceived fatigue score using a Numerical Rating Scale (NRS)

    Subjective physical fatigue is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low fatigue and 10 represents very high fatigue.

    Time frame: Twice daily (before and after each full work day) over the 12-day study protocol

  4. User satisfaction score with the non-motorized DAP (ESAT questionnaire)

    User satisfaction with the assistive device will be assessed using the 8-item Device subscale of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0 / ESAT). Items are rated on a 5-point Likert scale from 1 to 5, yielding a total sum score ranging from 8 to 40, where higher scores indicate greater satisfaction

    Time frame: At the end of Phase B (Day 6 of wearing the device)

  5. Acceptability score based on the UTAUT model

    Technology acceptance will be assessed across the constructs of the Unified Theory of Acceptance and Use of Technology (UTAUT) questionnaire. Each item is rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree). Each item also belongs one of several subscales. Mean scores are calculated separately for each subscale, ranging from 1 to 7, where higher scores indicate greater technology acceptance.

    Time frame: Baseline (prior to Phase A1/B) and Post-Intervention (At the end of day 6 of phase B)

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 251 non-industry interventional studies with no phase under Musculoskeletal Diseases, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 12 months is below that.

Counting every sponsor, half of 266 studies reached it within 16 months; a quarter within 6 and three quarters within 36.

Musculoskeletal Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941570
Lead sponsor
Pôle Saint Hélier
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Bastien Fraudet
Contact
bastien.fraudet@fondationsainthelier.com
+33299295043

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion